IRLAB THERAP. AB A
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms … Read more
IRLAB THERAP. AB A (6IRA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IRLAB THERAP. AB A (6IRA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IRLAB THERAP. AB A - Net Assets Trend (None–None)
This chart illustrates how IRLAB THERAP. AB A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IRLAB THERAP. AB A (None–None)
The table below shows the annual net assets of IRLAB THERAP. AB A from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IRLAB THERAP. AB A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IRLAB THERAP. AB A Competitors by Market Cap
The table below lists competitors of IRLAB THERAP. AB A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cadence Opportunities Fund Ltd
AU:CDO
|
$9.62 Million |
|
Chonburi Concrete Product Public Company Limited
BK:CCP
|
$9.62 Million |
|
Dongsung Pharm
KO:002210
|
$9.63 Million |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
$9.63 Million |
|
Murray & Roberts Holdings Limited
PINK:MURSF
|
$9.62 Million |
|
exax Inc
KQ:060230
|
$9.61 Million |
|
Magna Finance Tbk
JK:MGNA
|
$9.61 Million |
|
Bausen Inc.
TWO:2948
|
$9.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IRLAB THERAP. AB A's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IRLAB THERAP. AB A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IRLAB THERAP. AB A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IRLAB THERAP. AB A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IRLAB THERAP. AB A (6IRA) | €- | N/A | N/A | $9.62 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |